TerminatedNCT00645229
A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study evaluates the safety and effectiveness of Ziprasidone for people with schizophrenia.
Medication studyAges 18–60Portugal
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Ziprasidone for people with schizophrenia.
Who could participate?
Listed age limits: 18 years to 60 years.
- Listed locations
- LisbonSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateSeptember 2004
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 1
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Portugal
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00645229
- Official title
Show the full official title
Efficacy And Safety Of Ziprasidone In Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder, Including Patients With A Diagnosis Of Recent Onset
Recruitment & locations
TerminatedLisbon
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Ziprasidone for people with schizophrenia.
Who is behind this study?
The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Does this study involve medication?
Yes. The study involves medication, including Ziprasidone.
Who can participate?
Listed age limits: 18 years to 60 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
Efficacy and distinctive effects of atypical antipsychotics on cognitive symptoms in dual diagnosis – A phase IIIb, randomized, open-labelled study to evaluate the cognitive effects of quetiapine X...